Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 908-924

  Custodio, Ana ^a   Barriuso, Jorge ^a   de Castro, Javier ^a   Martínez Marín, Virginia ^a   Moreno, Víctor ^a   Rodríguez Salas, Nuria ^a   Feliu, Jaime ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiangiogenic therapy; Bevacizumab; Circulating biomarkers; Colorectal cancer; Pharmacogenetic biomarkers; Tissue biomarkers

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CARCINOEMBRYONIC ANTIGEN; CEDIRANIB; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; MICRORNA 126; MITOMYCIN; MOLECULAR MARKER; MONOCYTE CHEMOTACTIC PROTEIN 3; OXALIPLATIN; PLACEBO; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1BETA; THROMBOSPONDIN 1; THYMIDYLATE SYNTHASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

5' UNTRANSLATED REGION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLOOD SAMPLING; BLOOD VESSEL WALL; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CAPILLARY DENSITY; CHEMORADIOTHERAPY; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; COHORT ANALYSIS; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; FEASIBILITY STUDY; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; GENE INTERACTION; GENE LOCUS; GENOTYPE; GOOD LABORATORY PRACTICE; HALF LIFE TIME; HUMAN; IN VITRO STUDY; JAPANESE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIFACTOR DIMENSIONALITY REDUCTION; MULTIGENE FAMILY; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREDICTIVE VALUE; PRIMARY TUMOR; PROMOTER REGION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SCORING SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; STUDY DESIGN; SYSTEMIC THERAPY; TANDEM REPEAT; TISSUE MICROARRAY; TRANSCRIPTION INITIATION SITE; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR RESISTANCE; VALIDATION STUDY; VASCULAR ENDOTHELIUM;

ANTIANGIOGENIC THERAPY; BEVACIZUMAB; CIRCULATING BIOMARKERS; COLORECTAL CANCER; PHARMACOGENETIC BIOMARKERS; TISSUE BIOMARKERS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84883554603     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.02.004     Document Type: Review

References (174)

1. Bergers G., Benjamin L.E. Tumorigenesis and angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
3. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
4. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:77-684.
5. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
6. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009, 20:158-163.
7. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312:549-560.
8. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009, 29:789-791.
9. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
10. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
11. Aivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
12. Mizumaki Y., Jo W.S., Duerr E.M., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1 alpha-deficient colon cancer cells. Nat Rev 2005, 11:992-997.
13. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 478(7070):967-974.
14. Gerger A., LaBonte M., Lenz H.J. Molecular predictors or response to antiangiogenic therapies. Cancer J 2011, 17:134-141.
15. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
16. Starling N., Vázquez-Mazón F., Cunningham D., et al. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol 2012, 23:119-127.
17. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib motherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
18. Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based régimen. J Clin Oncol 2012, 30:3499-3506.
19. Fuchs C.S., Marshall J., Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008, 26:689-690.
20. Saltz L.B., Clarke S., Díaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
21. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
22. Masi G., Loupakis F., Salvatore L., et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:845-852.
23. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
24. Kozloff M., Yood M.U., Berlin L., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. The Oncologist 2009, 14:862-870.
25. Scartozzi M., Galizia E., Chiorrini S., et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009, 20:227-230.
26. De Stefano A., Carlomagmo C., Pepe S., Bianco R., de Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011, 68:1207-1213.
27. Van Heeckeren W.J., Ortiz J., Cooney M.M., Remick S.C. Hypertension, proteinuria and antagonism of vascular endothelial growth factor signalling: clinical toxicity, therapeutic target, or novel biomarker?. J Clin Oncol 2007, 25:2993-2995.
28. Ichante J.L., Adenis A., Francois E., et al. Impact of early tumour shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU+irinotecan+leucovorin (FOLFIRI) or capecitabine+irinotecan (XELIRI) plus bevacizumab. Eur J Cancer 2011, 47(SUPPL. 1):S419. Abstr 6094.
29. Chun Y.S., Vauthey J.N., Boonsirikamchai P., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009, 302:2338-2344.
30. Hirashima Y., Ymada Y., Tateishi U., et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorrectal cancer liver metastasis. Int J Cancer 2012, 130:2359-2365.
31. O'Connor J.B.P., Rose C.J., Jackson A., et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX6. Br J Cancer 2011, 105:139-145.
32. Carrillo-de Santa Pau E., Carrillo Arias F., Caso Peláez E., et al. Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 2010, 28:393-398.
33. Schmoll H., Hoff P.M., Robertson J.D., et al. Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC). J Clin Oncol 2009, 29(SUPPL.):3590. Abstr 3590.
34. Hoff P.M., Hochlaus A., Pestalozzi B.C., et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: A randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 2012, 30:3596-3603.
35. Schmoll H.J., Cunningham D., Sobrero A., et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012, 30:3588-3595.
36. Bernaards C., Hegde P., Chen D., et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. J Clin Oncol 2010, 28(SUPPL.):15s. Abstr 10519.
37. Keskin M., Ustuner Z., Dincer M., et al. Importance of serum VEGF and basic FGF levels in determining response to treatment and survival in patients with metastatic colorectal cancer. J Clin Oncol 2012, (SUPPL.):30. Abstr e21050.
38. Willett C.G., Duda D.G., di Tomaso E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
39. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
40. Yang J.C., Haworth L., Sherry R., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
41. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
42. Loupakis F., Falcone A., Masi G., et al. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamics marker for bevacizumab activity. J Clin Oncol 2007, 25:1816-1818.
43. Brostjan C., Gebhardt K., Gruenberger B., et al. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 2008, 14:2065-2074.
44. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRITE). J Clin Oncol 2008, 26:5326-5334.
45. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008, 14:6371-6375.
46. Shojaei F., Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008, 11:219-230.
47. Kopetz S., Hoff P.M., Morris J.S., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2009, 28:453-459.
48. Casanovas O., Hicklin D.J., Bergers G., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
49. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
50. Zhang Y.W., Su Y.L., Volpert O.V., et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003, 100:12718-12723.
51. Lieu C.H., Tran H.T., Jiang Z., et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J Clin Oncol 2011, (SUPPL.):29. Abstr 3533.
52. Loupakis F., Cremolini C., Fioravanti A., et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011, 104:1262-1269.
53. Allard W.J., Amtera J., Miller M.C., et al. Tumour cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
54. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumour cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
55. De Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumour cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
56. Cohen S.J., Punt C.J., Iannotti N., et al. Prognostic significance of circulating tumour cells in patients with metastatic colorectal cancer. Ann Oncol 2009, 20:1223-1229.
57. Cohen S.J., Punt C.J., Iannotti N., et al. Relationship of circulating tumour cells to tumour response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221.
58. Tol J., Koopman M., Miller M.C., et al. Circulating tumour cells early predict progression-free survival and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010, 21:1006-1012.
59. Sastre J., Maestro M.L., Gómez-España A., et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish cooperative group for the treatment of digestive tumors study. Oncologist 2012, 17:947-955.
60. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
61. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
62. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40.
63. Fukuhara S., Sako K., Noda K., et al. Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol 2010, 25:387-396.
64. Huang H., Bhat A., Woodnutt G., et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010, 10:575-585.
65. Bach F., Uddin F.J., Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007, 33:7-15.
66. Volkova E., Willis J.A., Wells J.E., Robinson B.A., Dachs G.U., Currie M.J. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 2011, 104:51-59.
67. Goede V., Coutelle O., Neuneier J., et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010, 103:1407-1414.
68. Strijbos M.H., Gratama J.W., Kraan J., et al. Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 2008, 98:1731-1735.
69. Rowand J.L., Martin G., Doyle G.V., et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 2007, 75:105-113.
70. Bertolini F., Mancuso P., Braidotti P., et al. The multiple personality disorder phenotypes of circulating endothelial cells in cancer. Bioch Biophys Acta 2009, 1976:27-32.
71. Martin-Pardura I., Bertolini F. The circulating endothelial cell in cancer: towards marker and target identification. Curr Pharm Des 2008, 14:3780-3789.
72. Gao D., Nolan D., McDonell K., et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009, 1796:33-40.
73. Norden-Zfoni A., Desai J., Manola J., et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007, 13:2643-2650.
74. Mancuso P., Colleoni M., Calleri A., et al. Circulating endothelial-cell kinetic and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006, 108:452-459.
75. Dellapasqua S., Bertolini F., Bagnardi V., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26:4899-4905.
76. Beaudry P., Force J., Naumov G.N., et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005, 11:3514-3522.
77. Li H., Raia V., Bertolini F., et al. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 2008, 101:884-888.
78. Ronzoni M., Manzoni M., Mariucci S., et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 2010, 21:2382-2389.
79. Simkens L.H.J., Tol J., Terstappen L.W.M.M., Teerenstra S., Punt C.J.A., Nagtegaal I.D. The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. Ann Oncol 2010, 21:2447-2448.
80. Mariucci S., Rovati B., Bencardino K., et al. Flow cytometry detection of circulating endothelial cells and endothelial progenitors cells in healthy subjects. Int J Lab Hematol 2010, 32:40-48.
81. Goon P.K., Boos C.J., Stonelake P.S., et al. Detection and quantification of mature circulating endothelial cells using a flow cytometry and immunomagnetic beads: a methodological comparison. Tromb Haemost 2006, 96:45-52.
82. Bencardino K., Manzoni M., Rovati B., et al. Flow cytometry determination of circulating endothelial cells in advanced colorectal cancer patients treated with bevacizumab-based combination therapy. Eur J Cancer 2007, 5:247. Abstr 3039.
83. Mancuso P., Antoniotti P., Quarna J., et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultraestructural analyses. Clin Cancer Res 2009, 15:267-273.
84. Rabascio C., Muratori E., Mancuso P., et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004, 64:4373-4377.
85. Lin E.H., Hassan M., Li Y. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer 2007, 110:534-542.
86. White J.D., Hewett P.W., Kosuge D., et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002, 62:1669-1675.
87. Cascinu S., Staccioli M.P., Gasparino G., et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000, 6:2803-2807.
88. Des Guetz G., Uzzan B., Nicolas P., et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006, 94:1823-1832.
89. Ning Y., Lurje G., Danenberg K., et al. VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer. J Clin Oncol 2009, 27(SUPPL.):15s. Abstr 4040.
90. Watanabe T., Kobunai T., Yamamoto Y., et al. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum 2011, 54:1026-1035.
91. Jubb A.M., Hurwitz H.I., Bai W. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
92. Foernzler D., Delmar P., Kockx M., et al. Tumor tissue based biomarker analysis in NO16966: a randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC. J Clin Oncol 2010, 23:456. Abstr 374 (Gastrointestinal Cancers Symposium).
93. Weickhardt A.J., Williams D., Lee C., et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX study. J Clin Oncol 2011, (SUPPL.):29. Abstr 3531.
94. El-Khouery A.B., Pohl A., Danenberg K., et al. WT Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol 2009, 27(SUPPL.):15. Abstr 4056.
95. Jubb A.M., Buffa F.M., Harris A.L. Assessment of tumor hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 2010, 14:18-29.
96. Cascinu S., Graziano F., Catalano V., et al. Vascular endothelial growth factor and p53 expression in liver and abdominal metastases from colon cancer. Tumour Biol 2003, 24:77-81.
97. Kuramochi H., Hayashi K., Uchida K., et al. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 2006, 12:29-33.
98. Smith N.R., Baker D., James N.H., et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010, 16:3548-3561.
99. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
100. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 2001, 17:25-51.
101. Bein K., Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2: regulation of metalloproteinase activity. J Biol Chem 2000, 275:32167-32173.
102. Allegrini G., Goulette F.A., Darnowski J.W., et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 2004, 53:261-266.
103. Nocci G., Francia G., Man S., et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003, 100:12917-12922.
104. Nakao T., Kurita N., Komatsu M., et al. Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol 2011, 16:145-152.
105. Okada K., Hirabayashi K., Imaizumi T., et al. Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas. Biomed Res 2010, 31:13-19.
106. Zhang X., Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res 2007, 74:90-99.
107. Tokunaga T., Nakamura M., Oshika Y., et al. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 1999, 79:354-359.
108. Galizia G., Lieto E., Ferraraccio Y., et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004, 10:3490-3499.
109. Li C., Gardy R., Seon B.K., et al. Both high intratumoral microvessel density determining using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003, 88:1424-1431.
110. Van Cutsem E., Köhne C.H., Láng I., et al. Cetuximab plus irinotecan, flourouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
111. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
112. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus cetuximab in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
113. Richman S.D., Seymour M.T., Chambers P., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009, 27:5931-5937.
114. Maughan T.S., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
115. Roth A., Tejpar S., Delorenzi M., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
116. Ciardiello F., Troiani T., Bianco R., et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multitarget anticancer therapy. Ann Oncol 2006, 17:vii109-vii114.
117. Ellis L.M. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004, 18:1007-1021.
118. Ince W.L., Jubb A.M., Scott N.H., et al. Association of K-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989.
119. Hurwitz H.I., Yi J., Ince W., Novotny W.F., Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22-28.
120. Díaz-Rubio E., Gómez-España A., Massutí B., et al. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One 2012, 7(10):e47345.
121. Sogabe S., Yuki S., Hayashi H., et al. Retrospective cohort study on the safety and efficacy of bevacizumab for metastatic colorectal cancer patients: the HGCSG0801 study- Efficacy of KRAS mutational status. J Clin Oncol 2012, Abstr 680 (Gastrointestinal Cancers Symposium).
122. Jürgensmeier J.M., Hoff P.M., Pike L. Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib. J Clin Oncol 2011, (SUPPL.):29. Abstr 3613.
123. García Alfonso P., Muñoz A.J., Álvarez S., et al. Prognostic value of KRAS in terms of efficacy and safety of bevacizumab as neoadjuvant or conversion treatment in patients with colorectal liver metastasis. J Clin Oncol 2012, (SUPPL.):30. Abstr e14058.
124. Bruera G., Cannita K., Di Giacomo D., et al. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (Flr-B/Fox) according to extension of metastatic disease. BMC Med 2012, 10:135.
125. Price T.J., Hardingham E., Lee C.K., et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011, 29:2675-2682.
126. Reinacher-Schick A.C., Arnold D., Kubicka S., et al. Impact of KRAS status on survival in patients (pts) with metastatic colorectal cancer (MCRC) undergoing bevacizumab (BEV) containing chemotherapy regimen-analysis of the AIO Colorectal Cancer Study Group. Ann Oncol 2010, (SUPPL. 8):21. Abstr 584PD.
127. Stintzing S., Fischer von Weikersthal L., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012, 23:1693-1699.
128. Ellis L.M. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 2006, 33(SUPPL. 10):S1-S7.
129. Bass A. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer. J Clin Oncol 2011, 29:2728-2729.
130. Boisen M.K., Dehlendorff C., Linnemann D., et al. Discovery of microRNAs in tumor tissue predictive of time to progression and overall survival in patients with colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab. J Clin Oncol 2012, (SUPPL. 4):30. Abstr 461.
131. Hansen T., Christensen R.P., Andersen R.F., et al. The relationship between microRNA-126 and maintenance therapy with bevacizumab after bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results of the phase III Nordic ACT trial NCT00598156 translational study. J Clin Oncol 2012, (SUPPL.):30. Abstr 3573.
132. Pasqualetti G., Danesi R., Del Tacca M., Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007, 8:49-66.
133. Jain L., Vargo C.A., Danesi R., et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009, 8:2496-2508.
134. Kim J.G., Chae Y.S., Sohn S.K., et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008, 14:62-66.
135. Lurje G., Zhang W., Schultheis A.M., et al. Polymorphisms in the VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008, 19:1734-1741.
136. Kjaer-Frifeldt S., Fredslund R., Lindebjerg J., Hansen T.F., Spindler K.L., Jakobsen A. Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. Pharmacogenomics 2012, 13:763-770.
137. Dong G., Guo X., Fu X., et al. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer. Cancer Sci 2012, 103:561-568.
138. Loupakis F., Ruzzo A., Salvatore L., et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011, 11:247.
139. Koutras A., Antonacopoulou A., Eleftheraki A.G., et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 2012, 12:468-475.
140. Formica V., Palmirotta R., del Monte G., et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011, 26:143-151.
141. Hansen T.F., Christensen R.D., Andersen R.F., Spindler K.L., Johnsson A., Jakobsen A. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis 2012, 27:715-720.
142. Murphy J.E., Liebman H.M., Zhou Q., et al. Functional SNPs in vascular endothelial growth factor (VEGF-A) and overall survival (OS) in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2012, (SUPPL.):30. Abstr 3594.
143. Cremolini C., Loupakis F., Yang D., et al. Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). J Clin Oncol 2012, (SUPPL.):30. Abstr 3518.
144. Lambrechts D., Delmar P., Miles D.W., et al. Single nucleotide polymorphism analysis and outcome in advanced-stage cancer patients treated with bevacizumab. Eur J Cancer 2011, 47(SUPPL. 1):S173. Abstr 1414.
145. Wilke R.A., Reif D.M., Moore J.H. Combinatorial pharmacogenetics. Nat Rev Drug Discov 2005, 4:911-918.
146. Moore J.H. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003, 56:73-82.
147. Pander J., Wessels J.A.M., Gelderblom H., van der Straaten T., Punt C.J.A., Guchelaar H.J. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol 2011, 22:1147-1153.
148. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010, 21:21-26.
149. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
150. Cao Y., Zhong W., Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol 2009, 19:338-343.
151. Knüpfer H., Preiss R. Serum interleukin-6 levels in colorectal cancer patients- a summary of published results. Int J Colorectal Dis 2010, 25:135-140.
152. Li A., Dubey S., Varney M.L., et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. L Immunol 2003, 170:3369-3376.
153. Strieter R.M., Burdick M.D., Mestas J., et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006, 42:768-778.
154. Ueda T., Shimada E., Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994, 29:423-429.
155. Hull J., Thompson A., Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000, 55:1023-1027.
156. Lee W.P., Tai D.I., Lan K.H., et al. The -251 T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res 2005, 11:6431-6441.
157. Ohyauchi M., Imatani A., Yonechi M., et al. The polymorphism interleukin 8-251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 2005, 54:330-335.
158. Zhang W., Stoehlmacher J., Park D.J., et al. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005, 5:124-131.
159. Gordon M.A., Gil J., Lu B., et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 2006, 7:67-88.
160. Gerger A., El-Khoueiry A., Zhang W., et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2011, 17:5783-5792.
161. Lee P.H., Shatkay H. F-SNP: computationally predicted functional SNP for disease association studies. Nucleic Acids Res 2008, 36:D820-D824.
162. Lee P.H., Shatkay H. An integrative scoring system for ranking SNPs by their potential deleterious effects. Bioinformatics 2009, 25:1048-1055.
163. Lanuti M., Liu G., Goodwin J.M., Zhai R., Fuchs B.C., Asomaning K., et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008, 14:3216-3222.
164. Pander J., Gelderblom H., Antonini N.F., et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010, 46:1829-1834.
165. Van Cruijsen H., Giaccone G., Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005, 117:883-888.
166. Verheus M., McKay J.D., Kaaks R., et al. Common genetic variation in the IGF-1 gene, serum IGF-I levels, and breast density. Breast Cancer Res Treat 2008, 112:109-122.
167. Jiang Z.Y., He Z., Zing B.L., et al. Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 2003, 278:31964-31971.
168. Fan F., Stoeltzing O., Liu W., et al. Interleukin-1 beta regulates angiopoietin-1 expression in human endothelial cells. Cancer Res 2004, 64:3186-3190.
169. Lurje G., Nagashima F., Zhang W., et al. Polymorphisms in COX-2 and EGFR are associated with progression-free survival independent of K-ras in mCRC patients treated with single agent cetuximab. Clin Cancer Res 2008, 14:7884-7895.
170. Bai B., Yamamoto K., Sato H., Sugiura H., Tanaka I. Combined effect of 25-hydroxycholesterol and IL-1beta on IL-8 production in human colon carcinoma cell line (Caco-2). Inflammation 2005, 29:141-146.
171. Danis V.A., Millington M., Hyland V.J., Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995, 99:303-310.
172. Lurje G., Hendifar A.E., Schultheis A.M., et al. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics 2009, 19:95-102.
173. Dai J., Wan S., Zhou F., et al. Genetic polymorphism in a VEGF-independent angiogenesis gene ANGPT1 and overall survival of colorectal cancer patients after surgical resection. PLoS One 2012, 7:e34758.
174. Thomas S.P., Badarinath S., Greenberg R.H., et al. MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC). J Clin Oncol 2012, (SUPPL.):30. Abstr TPS3635.